Strategic Investment Solutions Inc. IL Invests $112,000 in Kenvue Inc. (NYSE:KVUE)

by · The Cerbat Gem

Strategic Investment Solutions Inc. IL purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE – Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 4,854 shares of the company’s stock, valued at approximately $112,000.

A number of other hedge funds have also bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Kenvue by 12.0% during the first quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock worth $3,579,294,000 after acquiring an additional 17,908,497 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Kenvue by 23.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock worth $2,887,773,000 after acquiring an additional 25,238,112 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Kenvue by 9.6% during the second quarter. Massachusetts Financial Services Co. MA now owns 79,863,967 shares of the company’s stock worth $1,451,927,000 after acquiring an additional 7,023,047 shares during the period. JPMorgan Chase & Co. lifted its holdings in Kenvue by 11.1% during the first quarter. JPMorgan Chase & Co. now owns 68,319,998 shares of the company’s stock worth $1,466,147,000 after acquiring an additional 6,825,611 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Kenvue by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company’s stock worth $789,813,000 after acquiring an additional 7,546,362 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Price Performance

Kenvue stock traded down $0.11 during midday trading on Friday, hitting $22.86. 583,033 shares of the company’s stock were exchanged, compared to its average volume of 18,078,461. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $23.55. The stock has a 50-day moving average price of $22.39 and a two-hundred day moving average price of $20.28. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99. The company has a market cap of $43.77 billion, a P/E ratio of 29.43, a PEG ratio of 2.76 and a beta of 1.40.

Kenvue (NYSE:KVUE – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The firm had revenue of $4 billion during the quarter, compared to analyst estimates of $3.93 billion. During the same quarter in the previous year, the company posted $0.32 earnings per share. The company’s revenue was down .3% compared to the same quarter last year. On average, equities research analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.59%. The ex-dividend date is Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is currently 105.13%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Piper Sandler lifted their price target on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a report on Monday, September 23rd. UBS Group raised their target price on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. raised their target price on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Bank of America raised their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a research report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $22.64.

Check Out Our Latest Research Report on Kenvue

Kenvue Company Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Featured Articles

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).